Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
AbbVie (NY: ABBV)
86.64 USD  +0.20 (+0.23%)
Streaming Delayed Price  /  Updated: 2:38 PM EST, Dec 10, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 4,693,914
Open 86.92
Bid (Size) 86.63 (1)
Ask (Size) 86.64 (3)
Prev. Close 86.44
Today's Range 86.21 - 86.95
52wk Range 62.66 - 92.99
Shares Outstanding 1,586,879,451
Dividend Yield 4.14%
Performance
YTD
-2.91%
-2.91%
1 Month
+1.14%
+1.14%
3 Month
+29.89%
+29.89%
6 Month
+12.59%
+12.59%
1 Year
-1.11%
-1.11%
Top News
More News
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
Financialnewsmedia.com News Commentary Read More
from PR Newswire
More News
Read More
Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay
from GlobeNewswire News Releases
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
from PR Newswire
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Ly
from PR Newswire
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unr
from PR Newswire
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
from PR Newswire
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
from PR Newswire
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
from GlobeNewswire News Releases
5 Stocks Moving On ASH Presentations
category TGTX , ASH , Trading Ideas , and 17 more.
from Benzinga
Drugmakers have spent a record $342 billion on M&A in 2019
category Pharmaceuticals , Health/Care , MRK , and 19 more.
from MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.